Dr. Julia Foldi, MD, PhD
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Area of expertise
Breast Cancer
Julia Foldi, MD, PhD has run 6 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Julia Foldi, MD, PhD has run 5 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Pittsburgh Cancer Institute (UPCI)
University Of Pittsburgh Cancer Institute
Clinical Trials Julia Foldi, MD, PhD is currently running
ASTX727 + Paclitaxel + Pembrolizumab
for Breast Cancer
This phase I trial tests the safety, side effects, and best dose of ASTX727 when given in combination with a usual approach of treatment with paclitaxel and pembrolizumab in patients with triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). The usual approach is defined as care most people get for this type of cancer. The usual approach for patients with metastatic triple negative breast cancer who are not in a study is chemotherapy with drugs like paclitaxel, carboplatin, cisplatin, eribulin, vinorelbine, capecitabine, gemcitabine, doxorubicin or cyclophosphamide. There is a protein called PD-L1 that helps regulate the body's immune system. For patients who have PD-L1+ tumors, immunotherapy (pembrolizumab) is usually added to paclitaxel or carboplatin/gemcitabine as initial treatment. For patients who have PD-L1-negative tumors, chemotherapy alone is used, without immunotherapy. ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ASTX727 with usual treatment approach with paclitaxel and pembrolizumab may be able to shrink or stabilize the tumor for longer than the usual approach alone in patients with metastatic triple negative breast cancer.
Recruiting
1 award
Phase 1
23 criteria
Vaccine + Chemotherapy + Immunotherapy
for Breast Cancer
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.
Recruiting
1 award
Phase 2
22 criteria
More about Julia Foldi, MD, PhD
Clinical Trial Related
2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Julia Foldi, MD, PhD has experience with
- Pembrolizumab
- Binimetinib
- Fulvestrant
- Copanlisib Hydrochloride
- Eribulin Mesylate
- Paclitaxel
Breakdown of trials Julia Foldi, MD, PhD has run
Breast Cancer
Breast cancer
Chest Wall Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Julia Foldi, MD, PhD specialize in?
Julia Foldi, MD, PhD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Julia Foldi, MD, PhD currently recruiting for clinical trials?
Yes, Julia Foldi, MD, PhD is currently recruiting for 2 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Julia Foldi, MD, PhD has studied deeply?
Yes, Julia Foldi, MD, PhD has studied treatments such as Pembrolizumab, Binimetinib, Fulvestrant.
What is the best way to schedule an appointment with Julia Foldi, MD, PhD?
Apply for one of the trials that Julia Foldi, MD, PhD is conducting.
What is the office address of Julia Foldi, MD, PhD?
The office of Julia Foldi, MD, PhD is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.